Long-Term Use of Guselkumab: Non-interventional Assessment of Real-world Outcomes
The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
• Must be eligible for biologic treatment and initiate guselkumab according to the approved indications as described in the current version of the summary of product characteristics (SmPC) of drug. Decision to prescribe must solely be made by the treating physician. Enrolment must take place before or on the day of the first administration (but after treatment decision by physician)
• Must have confirmed diagnosis of moderate-to-severe UC or CD disease record in their medical records
• Must sign a participation agreement/Informed consent form (ICF) allowing source data verification in accordance with local requirements